These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 26324706)

  • 21. Structural insight into inactivation of plasminogen activator inhibitor-1 by a small-molecule antagonist.
    Lin Z; Jensen JK; Hong Z; Shi X; Hu L; Andreasen PA; Huang M
    Chem Biol; 2013 Feb; 20(2):253-61. PubMed ID: 23438754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.
    Rodenburg KW; Kjoller L; Petersen HH; Andreasen PA
    Biochem J; 1998 Jan; 329 ( Pt 1)(Pt 1):55-63. PubMed ID: 9405275
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reversible interactions between plasminogen activators and plasminogen activator inhibitor-1.
    Mimuro J; Kaneko M; Murakami T; Matsuda M; Sakata Y
    Biochim Biophys Acta; 1992 Dec; 1160(3):325-34. PubMed ID: 1477106
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ELISA for complexes of urokinase-type and tissue-type plasminogen activators with their type-1 inhibitor (uPA-PAI-1 and tPA-PAI-1).
    Grebenschikov N; Sweep F; Geurts A; Andreasen P; De Witte H; Schousboe S; Heuvel J; Benraad T
    Int J Cancer; 1999 May; 81(4):598-606. PubMed ID: 10225451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Engineering plasminogen activator inhibitor 1 mutants with increased functional stability.
    Lawrence DA; Olson ST; Palaniappan S; Ginsburg D
    Biochemistry; 1994 Mar; 33(12):3643-8. PubMed ID: 8142362
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasminogen activator inhibitor type-1 interacts exclusively with the proteinase domain of tissue plasminogen activator.
    Björquist P; Brohlin M; Ehnebom J; Ericsson M; Kristiansen C; Pohl G; Deinum J
    Biochim Biophys Acta; 1994 Dec; 1209(2):191-202. PubMed ID: 7811690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterisation of the complex of plasminogen activator inhibitor type 1 with tissue-type plasminogen activator by mass spectrometry and size-exclusion chromatography.
    Strömqvist M; Karlsson KE; Björquist P; Andersson JO; Byström M; Hansson L; Johansson T; Deinum J
    Biochim Biophys Acta; 1996 Jun; 1295(1):103-9. PubMed ID: 8679667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epitopes on plasminogen activator inhibitor type-1 important for binding to tissue plasminogen activator.
    Björquist P; Ehnebom J; Inghardt T; Deinum J
    Biochim Biophys Acta; 1997 Aug; 1341(1):87-98. PubMed ID: 9300812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
    Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
    Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recognition of Plasminogen Activator Inhibitor Type 1 as the Primary Regulator of Fibrinolysis.
    Urano T; Suzuki Y; Iwaki T; Sano H; Honkura N; Castellino FJ
    Curr Drug Targets; 2019; 20(16):1695-1701. PubMed ID: 31309890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biological mechanisms underlying the clinical effects of RU 486: modulation of cultured endometrial stromal cell plasminogen activator and plasminogen activator inhibitor expression.
    Lockwood CJ; Krikun G; Papp C; Aigner S; Schatz F
    J Clin Endocrinol Metab; 1995 Apr; 80(4):1100-5. PubMed ID: 7714076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasminogen activator levels are influenced by location and varicosity in greater saphenous vein.
    Shireman PK; McCarthy WJ; Pearce WH; Shively VP; Cipollone M; Kwaan HC; Yao JS
    J Vasc Surg; 1996 Nov; 24(5):719-24. PubMed ID: 8918314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Remarkable extension of PAI-1 half-life surprisingly brings no changes to its structure.
    Jankun J; Yang J; Zheng H; Han FQ; Al-Senaidy A; Skrzypczak-Jankun E
    Int J Mol Med; 2012 Jan; 29(1):61-4. PubMed ID: 21947232
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of the plasminogen activator system in the human vascular wall.
    Salame MY; Samani NJ; Masood I; deBono DP
    Atherosclerosis; 2000 Sep; 152(1):19-28. PubMed ID: 10996335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A truncated plasminogen activator inhibitor-1 protein induces and inhibits angiostatin (kringles 1-3), a plasminogen cleavage product.
    Mulligan-Kehoe MJ; Wagner R; Wieland C; Powell R
    J Biol Chem; 2001 Mar; 276(11):8588-96. PubMed ID: 11113116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of thrombin on steroid-modulated cultured endometrial stromal cell fibrinolytic potential.
    Lockwood CJ; Krikun G; Aigner S; Schatz F
    J Clin Endocrinol Metab; 1996 Jan; 81(1):107-12. PubMed ID: 8550736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery and characterisation of an antibody that selectively modulates the inhibitory activity of plasminogen activator inhibitor-1.
    Vousden KA; Lundqvist T; Popovic B; Naiman B; Carruthers AM; Newton P; Johnson DJD; Pomowski A; Wilkinson T; Dufner P; de Mendez I; Mallinder PR; Murray C; Strain M; Connor J; Murray LA; Sleeman MA; Lowe DC; Huntington JA; Vaughan TJ
    Sci Rep; 2019 Feb; 9(1):1605. PubMed ID: 30733557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization and comparative evaluation of a structurally unique PAI-1 inhibitor exhibiting oral in-vivo efficacy.
    Crandall DL; Elokdah H; Di L; Hennan JK; Gorlatova NV; Lawrence DA
    J Thromb Haemost; 2004 Aug; 2(8):1422-8. PubMed ID: 15304050
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of tissue type and urokinase type plasminogen activators as well as plasminogen activator inhibitor type-1 and type-2 in human and rhesus monkey placenta.
    Hu ZY; Liu YX; Liu K; Byrne S; Ny T; Feng Q; Ockleford CD
    J Anat; 1999 Feb; 194 ( Pt 2)(Pt 2):183-95. PubMed ID: 10337950
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TM5275 prolongs secreted tissue plasminogen activator retention and enhances fibrinolysis on vascular endothelial cells.
    Yasui H; Suzuki Y; Sano H; Suda T; Chida K; Dan T; Miyata T; Urano T
    Thromb Res; 2013 Jul; 132(1):100-5. PubMed ID: 23611258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.